beeldscherm schreef op 30 april 2018 12:12:
[...]
..Scope of Comparative Value Analyses
As a complement to the evidence review, we will develop a de novo simulation model to assess the
lifetime cost-effectiveness of lanadelumab, Haegarda, Cinryze, and Ruconest for long-term
prophylaxis against acute attacks of HAE-1/2, compared to no prophylaxis.
benieuwd hoe Pha zich hierin verhoudt..